Ajanta Pharma Limited
Ajanta Tower, 54-A, M Vasanji Road,
Chakala, Andheri (E),
Mumbai – 400 093, India

T +91 22 6060 9000
E corpcom@ajantapharma.com
W www.ajantapharma.com

Great Place To Work. Certified FEB 2026-FEB 2027 INDIA

Press Release

Revenue up by 33% and PAT up by 49%

(2nd Quarter FY 2027 Consolidated Results)

Mumbai, 30th October, 2026: Ajanta Pharma Ltd., a specialty pharmaceutical formulation company today reported its excellent performance for 2nd quarter, and half year ended 30th September 2026.

Q2 FY 2027 performance highlights (compared to Q2 FY 2026):

- Revenue from operations at **Rs. 1,794 cr.** against Rs. 1,354 cr.; **up 33%**.
- Adjusted EBITDA (excluding forex loss) at **Rs. 543 cr.** & **30%** against Rs. 369 cr., up 47%.
- Profit after tax at **Rs. 388 cr.** against Rs. 260 cr.; PAT at 22%; **up 49%**.

H1 FY 2027 performance highlights (compared to H1 FY 2026):

- Revenue from operations at **Rs. 3,420 cr.** against Rs. 2,656 cr.; **up 29%**.
- Adjusted EBITDA (excluding forex loss) at **Rs. 997 cr.** & **29%** against Rs. 745 cr., up 34%.
- Profit after tax at **Rs. 722 cr.** against Rs. 516 cr.; PAT at 21%; **up 40%**.
- ROCE stood at a healthy level of 41% and RONW at 31%.

Segment wise performance:

(Rs. cr.)

Markets	Q2		Gwth%	H1		Gwth%
	FY 2026	FY 2027		FY 2026	FY 2027	
Branded Generics						
India	₹ 432	₹ 504	16%	₹ 841	₹ 1,013	20%
Asia	₹ 310	₹ 366	18%	₹ 614	₹ 621	1%
Africa	₹ 221	₹ 312	41%	₹ 449	₹ 607	35%
Sub-Total	**₹ 963**	**₹ 1,182**	**23%**	**₹ 1,904**	**₹ 2,241**	**18%**
US Generic	**₹ 344**	**₹ 484**	**41%**	**₹ 653**	**₹ 971**	**49%**
Africa Institution	**₹ 32**	**₹ 116**	**259%**	**₹ 71**	**₹ 187**	**164%**
Total	**₹ 1,339**	**₹ 1,782**	**33%**	**₹ 2,628**	**₹ 3,399**	**29%**

As per **IQVIA MAT September 2026**, our India branded generic performance exceeded IPM growth by **27%**. The higher growth came from new launches, which exceeded IPM by **70%** & volumes, which exceeded IPM by **18%**.

Ajanta Pharma Limited
Ajanta Tower, 54-A, M Vasanji Road,
Chakala, Andheri (E),
Mumbai – 400 093, India

T +91 22 6060 9000
E corpcom@ajantapharma.com
W www.ajantapharma.com

India branded generic segment wise performance as per IQVIA MAT September 2026 against IPM is as below:

Therapy	Growth %	
	IPM	Ajanta
Cardiology	17%	13%
Ophthalmology	12%	18%
Dermatology	11%	14%
Pain Management	13%	16%
Overall	**13%**	**17%**

Though our Cardiology growth looks lower than IPM as per IQVIA due to some anomaly in the working, our internal growth is at par with the IPM.

ANDA status as at the end of H1 FY 2027 is as below:

Particulars	H1 FY 2027
Filed	1
Approval received	4
Launched	3
Total ANDA's commercialized	52
Awaiting approval with US FDA	17
Tentative approval	5

R&D expense:

(Rs. cr.)

Particulars	FY 2026	FY 2027	% to Revenue
Q2	₹ 63	₹ 72	4%
H1	₹ 119	₹ 138	4%

About Ajanta Pharma Limited

Ajanta Pharma is a speciality pharmaceutical formulation company having major focus on branded generic business across India, Asia & Africa. Company has ground presence in each of these 34+ countries. Many of company's products are 1st to market and are leading in their sub-therapeutic segments. Company also has presence in USA in generic business and institution business in Africa.

Company's state of the art R&D centre is in Mumbai. Company has 7 world class manufacturing facilities located in India.

For the last 3 financial years, company has posted healthy Revenue and PAT CAGR of 14%.

Ajanta Pharma Limited
Ajanta Tower, 54-A, M Vasanji Road,
Chakala, Andheri (E),
Mumbai – 400 093, India

T +91 22 6060 9000
E corpcom@ajantapharma.com
W www.ajantapharma.com

Earnings Conference Call

The Company will host an Earnings Conference Call at 16:00 hrs. IST (18:30 hrs. SST/HKT, 10:30 hrs. GMT, 06:30 hrs. US ET), during which the leadership team will discuss the financial performance and take questions. A transcript of the conference call will be available at www.ajantapharma.com.

Dial-in Information

Date and Time	**October 30, 2026** at 16:00 – 17:00 hrs IST 18:30 – 19:30 hrs SST/HKT 10:30 – 11:30 hrs GMT 06:30 – 07:30 hrs US ET
Dial-in Numbers	
Diamond pass link for faster access	Click here to register
Universal Access	Primary Access: **(+91 22 6280 1542)** **(+91 22 7115 8372)**
International Toll Free	USA: **18667462133** UK: **08081011573** Hong Kong: **800964448** Singapore: **8001012045**

For convenience and faster connectivity to the conference, kindly follow the below steps:

1. Register through the Diamond pass link.
2. You will receive a calendar invite along with a passcode and a PIN number. The passcode and PIN will be activated 30 minutes prior to the conference scheduled time.
3. Dial the 'conference Dial-in number' you will receive on your email.
4. On system prompt dial the PASSCODE followed by # key.
5. On system prompt enter the PIN followed by # key.
6. If the line gets disconnected, you need to dial the 'conference dial-in number' again and follow the necessary steps.

Playback of Earnings Conference Call audio:

Playback of the earnings call will be available 120 minutes after the end of the call on our website (www.ajantapharma.com).

For more details visit www.ajantapharma.com
For regular updates follow us on x.com – https://x.com/AjantaPharmaLtd

For specific queries, contact:

Rajeev Agarwal Tel: +91 22 6060 9706 Email: rajeev.agarwal@ajantapharma.com
Abhineet Kumar Tel: +91 22 6060 9721 Email: abhineet.kumar@ajantapharma.com

Reuters: AJPH.NS, Bloomberg: AJP:IN, NSE: AJANTPHARM, BSE: 532331
Corporate Identity Number (CIN): L24230MH1979PLC022059

Safe Harbour Statement